to evaluate whether this treatment could be therapeutic. At the 
same time, these studies may also determine whether it is 
appropriate to express this gene, alone or in combination with 
others in hematopoietic stem cells in the future. 
The aim of this proposal is to determine whether expression 
of a specific recombinant gene can prolong the survival of 
peripheral blood lymphocytes in AIDS patients. This recombinant 
gene is derived from the rev gene of the human immunodeficiency 
virus (HIV) . A mutant form of rev . Rev M10, inhibits productive 
virus replication in cells susceptible to HIV infection. We will 
introduce a retroviral vector encoding Rev M10 and a control 
vector containing a frameshift mutation leading to an 
untranslated mRNA (ARev M10) into peripheral blood lymphocytes 
with retroviral vectors to determine: 
1) whether expression of Rev M10 in peripheral blood 
lymphocytes improves cell survival in comparison to 
control cells transduced with ARev M10. 
2) the effect of this treatment upon viral replication and 
immune function in vivo. 
Recombinant DNA Research, Volume 18 
[ 11 ] 
